NCT06537934 Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
| NCT ID | NCT06537934 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Interstitial Lung Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 123 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 123 participants in total. It began in 2024-09-01 with a primary completion date of 2025-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Interstitial lung diseases (ILDs) are common chronic disease characterized by high mortality and morbidity, also linked to cardiovascular implication. Cardiovascular complications, occur early in idiopathic pulmonary fibrosis (IPF) and other ILDs without anysymptoms. Symptoms are often misinterpreted and diagnosis delayed to irreversible stages of cardiac dysfunction. Mechanism of cardiac damage, the main cause of mortality, are heterogeneous raging from ischemic heart disease, acceleration of atherosclerosis, to right ventricle dysfunction secondary, to pulmonary hypertension. So an early recognition and accurate staging are fundamental to avoid disease progression and improve outcomes. The identification of a single non-invasive imaging modality able to simultaneously characterize in an accurate and quantitative way the entity of lung and cardiac damage in patients affected by ILD would be useful to improve risk stratification and to guide treatment.
Eligibility Criteria
Inclusion Criteria: • Adult subjects (\>18 y.o.) with previously known ILD or high likelihood for having ILD including CTD diagnosis since at least 5 years before the project starts in order to increase the prevalence of ILD \[2\] who signed an Informed Consent authorizing data collection. Exclusion Criteria: * Subjects with active infectious disease; * known CAD; * history of previous percutaneous or surgical revascularization; * known cardiomyopathy; * previous heart failure; * presence of cardiac devices (prosthetic valve, ICD, PM, ICD-CRT, LVAD) * previous or active neoplasia; * pregnancy and breastfeeding; * allergy to iodine contrast agent; * claustrophobia; * glomerular filtration rate \< 30mL/min * impossibility to lay down or breath old * absence of informed consent signed
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06537934 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06537934 currently recruiting?
Yes, NCT06537934 is actively recruiting participants. Contact the research team at palmisano.anna@hsr.it for enrollment information.
Where is the NCT06537934 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06537934 clinical trial?
NCT06537934 is sponsored by IRCCS San Raffaele. The trial plans to enroll 123 participants.